vinflunine
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transitional Cell Carcinoma
Conditions
Transitional Cell Carcinoma, Bladder Neoplasms, Kidney Neoplasms, Ureter Neoplasms, Bladder Cancer, Neoplasm, Bladder
Trial Timeline
Jan 1, 2005 → Apr 1, 2007
NCT ID
NCT00101608About vinflunine
vinflunine is a phase 2 stage product being developed by Bristol Myers Squibb for Transitional Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT00101608. Target conditions include Transitional Cell Carcinoma, Bladder Neoplasms, Kidney Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00545766 | Phase 2 | Completed |
| NCT00359476 | Phase 2/3 | Terminated |
| NCT00284154 | Phase 2 | Completed |
| NCT00251446 | Phase 2 | Completed |
| NCT00101608 | Phase 2 | Completed |
Competing Products
20 competing products in Transitional Cell Carcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine | Astellas Pharma | Phase 1/2 | 41 |
| Pemetrexed + Gemcitabine + Platinol | Eli Lilly | Phase 1/2 | 41 |
| Vepugratinib + EV + Pembrolizumab | Eli Lilly | Phase 3 | 77 |
| durvalumab and tremelimumab | AstraZeneca | Phase 2 | 52 |
| Docetaxel + vandetanib + Placebo | AstraZeneca | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Everolimus + Everolimus + Paclitaxel | Novartis | Phase 2 | 52 |
| Buparlisib | Novartis | Phase 2 | 52 |
| BEZ235 | Novartis | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Gemcitabine + Cisplatin + Sunitinib Malate | Pfizer | Phase 2 | 51 |
| Nivolumab/Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| vinflunine and best supportive care | Bristol Myers Squibb | Phase 3 | 76 |
| Dasatinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Docetaxel + Oxaliplatin | Sanofi | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2/3 | 64 |
| Rogaratinib (BAY1163877) + Chemotherapy | Bayer | Phase 2/3 | 62 |
| CG0070 Adenovirus Vector | CG Oncology | Phase 2/3 | 62 |